CSIMarket
 


Teligent Inc   (TLGT)
Other Ticker:  
 

Teligent Inc 's Quick Ratio

TLGT's quarterly Quick Ratio and Cash & cash equivalent, Current Liabilities growth


Regardless of the sequential decrease in Current Liabilities, during the second quarter 2021, Quick Ratio deteriorated to 1.8 below Teligent Inc 's average Quick Ratio.

Within Major Pharmaceutical Preparations industry 477 other companies have achieved higher Quick Ratio than Teligent Inc in second quarter 2021. While Quick Ratio total ranking in the second quarter 2021 has deteriorated compared to the prior quarter from 1534 to 2047.

Explain Quick Ratio?
How much Cash & cash equivalents TLGTīs has?
What are TLGTīs Current Liabilities?


TLGT Quick Ratio (Jun 30 2021)
II. Quarter
(Mar 31 2021)
I. Quarter
(Dec 31 2020)
IV. Quarter
(Sep 30 2020)
III. Quarter
(Jun 30 2020)
II. Quarter
Y / Y Current Liabilities Change -47.06 % -25.51 % 39.23 % -47.08 % -17.18 %
Y / Y Cash & cash equivalent Change 286.7 % 148.95 % -61.66 % 44.6 % 41.98 %
Quick Ratio MRQ 1.8 2.03 0.26 0.52 0.25
TLGT's Total Ranking # 2047 # 1534 # 3516 # 2736 # 3229
Seq. Current Liabilities Change -6.88 % -41.62 % 24.93 % -22.05 % 31.03 %
Seq. Cash & cash equivalent Change -17.59 % 361.72 % -38.69 % 65.75 % -46.94 %



Quick Ratio second quarter 2021 Company Ranking
Within: No.
Major Pharmaceutical Preparations Industry # 478
Healthcare Sector # 851
Overall Market # 2047


Quick Ratio Statistics
High Average Low
22.69 3.57 0.14
(Dec 31 2014)   (Jun 30 2019)




Financial Statements
Teligent Inc 's Current Liabilities $ 13 Millions Visit TLGT's Balance sheet
Teligent Inc 's Cash & cash equivalent $ 23 Millions Visit TLGT's Balance sheet
Source of TLGT's Sales Visit TLGT's Sales by Geography


Cumulative Teligent Inc 's Quick Ratio

TLGT's Quick Ratio for the trailling 12 Months

TLGT Quick Ratio

(Jun 30 2021)
II. Quarter
(Mar 31 2021)
I. Quarter
(Dec 31 2020)
IV. Quarter
(Sep 30 2020)
III. Quarter
(Jun 30 2020)
II. Quarter
Y / Y Current Liabilities TTM Growth -47.06 % -25.51 % 39.23 % -47.08 % -17.18 %
Y / Y Cash & cash equivalent TTM Growth 286.7 % 148.95 % -61.66 % 44.6 % 41.98 %
Quick Ratio TTM 0.97 0.62 0.39 0.55 0.42
Total Ranking TTM # 2082 # 2665 # 3027 # 2431 # 2608
Seq. Current Liabilities TTM Growth -6.88 % -41.62 % 24.93 % -22.05 % 31.03 %
Seq. Cash & cash equivalent TTM Growth -17.59 % 361.72 % -38.69 % 65.75 % -46.94 %


On the trailing twelve months basis TLGT Cash & cash equivalent more than doubled by 286.7 % in II Quarter 2021 year on year, while Current Liabilities decreased to $13 millions, this led to increase in in Teligent Inc 's Quick Ratio to 0.97, Quick Ratio remained below TLGT average.
Quick Ratio is the average cumulative value over the last four quarters.

Among companies operating within Major Pharmaceutical Preparations industry 512 other companies have achieved higher Quick Ratio than Teligent Inc . While Quick Ratio overall ranking has improved so far to 1391, from total ranking during the twelve months ending first quarter 2021 at 4760.

Explain Quick Ratio?
How much Cash & cash equivalents TLGTīs has?
What are TLGTīs Current Liabilities?

TTM Quick Ratio Company Ranking
Within: No.
Within the Major Pharmaceutical Preparations Industry # 513
Healthcare Sector # 1002
Within the Market # 2047


trailing twelve months Quick Ratio Statistics
High Average Low
9.2 2.5 0.21
(June 30. 2015)   (Sep 30 2019)




Companies with similar Quick Ratio in the quarter ending Jun 30 2021, within Major Pharmaceutical Preparations Industry Quick RatioJun 30 2021 MRQ Cash & cash equivalentJun 30 2021 MRQ Current Liabilities
China Health Industries Holdings Inc   4.87 $ 44.347  Millions$ 9.114  Millions
Aeon Biopharma inc   4.79 $ 0.989  Millions$ 0.206  Millions
Beyondspring Inc   4.78 $ 72.368  Millions$ 15.155  Millions
Summit Therapeutics Inc   4.72 $ 103.386  Millions$ 21.888  Millions
Panbela Therapeutics Inc   4.60 $ 6.405  Millions$ 1.393  Millions
Xeris Biopharma Holdings Inc   4.57 $ 115.980  Millions$ 25.364  Millions
Cti Biopharma Corp   4.55 $ 71.881  Millions$ 15.789  Millions
Therapeuticsmd Inc   4.54 $ 111.424  Millions$ 24.565  Millions
Biovie Inc   4.53 $ 4.512  Millions$ 0.996  Millions
Molecular Templates inc   4.47 $ 197.602  Millions$ 44.236  Millions
Ascendis Pharma A  4.46 $ 500.819  Millions$ 112.399  Millions
Leap Therapeutics inc   4.44 $ 35.734  Millions$ 8.056  Millions
Cue Biopharma Inc   4.43 $ 73.920  Millions$ 16.673  Millions
Cohbar Inc   4.41 $ 13.824  Millions$ 3.134  Millions
Harmony Biosciences Holdings inc   4.36 $ 159.686  Millions$ 36.595  Millions
Zymeworks Inc   4.33 $ 359.811  Millions$ 83.005  Millions
Zosano Pharma Corporation  4.33 $ 22.058  Millions$ 5.098  Millions
Aurinia Pharmaceuticals Inc   4.31 $ 121.561  Millions$ 28.203  Millions
Novabay Pharmaceuticals Inc   4.31 $ 10.294  Millions$ 2.389  Millions
Chimerix Inc   4.28 $ 106.584  Millions$ 24.922  Millions
Karyopharm Therapeutics Inc   4.22 $ 236.652  Millions$ 56.044  Millions
Adamas Pharmaceuticals Inc  4.19 $ 91.370  Millions$ 21.824  Millions
Regulus Therapeutics Inc   4.16 $ 41.440  Millions$ 9.968  Millions
Ac Immune Sa  4.11 $ 82.216  Millions$ 20.026  Millions
Pharming Group N v   4.10 $ 191.924  Millions$ 46.771  Millions
Fsd Pharma Inc   4.05 $ 35.260  Millions$ 8.701  Millions
Precigen Inc   3.99 $ 115.106  Millions$ 28.869  Millions
Phasebio Pharmaceuticals Inc.  3.99 $ 64.456  Millions$ 16.174  Millions
Galera Therapeutics Inc   3.95 $ 66.527  Millions$ 16.843  Millions
Theravance Biopharma inc   3.95 $ 264.953  Millions$ 67.127  Millions

Date modified: -0001-11-30T00:00:00+00:00



Help

About us

Advertise

CSIMarket Company, Sector, Industry, Market Analysis, Stock Quotes, Earnings, Economy, News and Research. 
   Copyright Đ 2024 CSIMarket, Inc. All rights reserved. This site uses cookies to make your browsing experince better. By using this site, you agree to the Terms of Service and Privacy Policy - UPDATED (Read about our Privacy Policy)

Intraday data delayed per exchange requirements. All quotes are in local exchange time. Intraday data delayed 15 minutes for Nasdaq, and other exchanges. Fundamental and financial data for Stocks, Sector, Industry, and Economic Indicators provided by CSIMarket.com